Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Scienture Holdings, Inc. - Common Stock (NQ:SCNX)

0.5740 +0.0526 (+10.09%)
Streaming Delayed Price Updated: 1:44 PM EST, Dec 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Scienture Holdings, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Why Is Scienture Stock Rising Today? ↗
Scienture has commenced selling Arbli, the first FDA-approved ready-to-use liquid losartan formulation. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Specificity (OTCQB: SPTY) Soars as New Leadership Ignites Global Ad Tech Expansion – More Stocks Inside
Via AB Newswire
News headline image
These stocks are gapping in today's session ↗
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
News headline image
Dow Gains 50 Points; Tesla Shares Slide After Q3 Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
Wondering what's happening in today's pre-market session? ↗
Discover the top movers in Thursday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
EXCLUSIVE: Scienture Launches Arbli Oral Suspension, Expanding Options For Hypertension Patients ↗
Scienture launches Arbli, the first FDA-approved liquid losartan, expanding hypertension treatment access across US healthcare institutions. 
Via Benzinga
News headline image
Top 3 Health Care Stocks You'll Regret Missing In October ↗
 
Via Benzinga
News headline image
EXCLUSIVE: Scienture Secures Hypertension Drug Purchase Agreements With 2,500 Healthcare Institutions ↗
Scienture Holdings, Inc. announced GPO agreements for its new drug, Arbli, providing access to over 2,500 healthcare institutions and plans to expand further. 
Via Benzinga
News headline image
EXCLUSIVE: Scienture Secures PBM-Led Rebate Agreement To Position Hypertension Drug For Rapid Adoption In US Market ↗
Scienture's Arbli, the first ready-to-use liquid losartan, gains formulary access with coverage for over 100 million lives and discussions for broader access. 
Via Benzinga
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Thursday's session: top gainers and losers ↗
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday. 
Via Chartmill
News headline image
Dow Falls Over 100 Points; Deere Shares Dip After Q3 Results ↗
 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Top movers in Tuesday's session ↗
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
What's Going On With Scienture Shares Tuesday? ↗
Scienture shares originally traded higher on Tuesday but have since reversed and began trading lower after the company announced the FDA approved its new drug application for Arbli. 
Via Benzinga
News headline image
Discover the top movers in Tuesday's pre-market session. ↗
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Top movers in Monday's after hours session ↗
As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
News headline image
Monday's session: top gainers and losers ↗
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Intrigued by the market activity in the middle of the day on Monday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Unusual volume stocks in Thursday's session ↗
Let's have a look at what is happening on the US markets on Thursday. Below you can find the stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.